{"created":"2023-05-15T14:42:45.225455+00:00","id":58582,"links":{},"metadata":{"_buckets":{"deposit":"b7dcb729-59b1-430a-8d67-393fd73160aa"},"_deposit":{"created_by":1,"id":"58582","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"58582"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00058582","sets":["11"]},"author_link":["585520","585525","585521","585523","585524","585522"],"item_10004_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2015-09","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"18","bibliographicPageStart":"16","bibliographicVolumeNumber":"31","bibliographic_titles":[{"bibliographic_title":"PET Journal"}]}]},"item_10004_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"放射性同位元素（RI）を用いた標的アイソトープ治療は、根治が難しい転移を持つがん腫の全身療法の役割を持つ。我が国ではI-131を用いた甲状腺がんの治療として保険収載され臨床応用されている。従来の標的アイソトープ治療用の放射性薬剤は標的細胞への薬剤送達が生理的機序によるものに限定されており治療の種類も限定されていた。近年、がん表面抗原に関する研究の進展から抗体などを利用した新たな標的細胞への薬剤送達法が開発され新世代の薬剤開発が海外で活発化している。さらに米国にてα線核種であるRa-223による前立腺癌のホルモン治療抵抗性骨転移に対する治療がFDA承認となり、従来のβ線放出核種による治療効果の限界を超える治療法の出現として注目を集めており、Ra-223の普及を契機とし国内外で新たな標的アイソトープ治療法の開発研究が進み始めている。","subitem_description_type":"Abstract"}]},"item_10004_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"先端医療技術研究所"}]},"item_10004_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"2186-022X","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"吉永, 恵一郎"}],"nameIdentifiers":[{"nameIdentifier":"585520","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"辻, 厚至"}],"nameIdentifiers":[{"nameIdentifier":"585521","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"永津, 弘太郎"}],"nameIdentifiers":[{"nameIdentifier":"585522","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"吉永 恵一郎","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"585523","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"辻 厚至","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"585524","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"永津 弘太郎","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"585525","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"標的アイソトープ治療　-最近の進歩と今後の展望-","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"標的アイソトープ治療　-最近の進歩と今後の展望-"}]},"item_type_id":"10004","owner":"1","path":["11"],"pubdate":{"attribute_name":"公開日","attribute_value":"2015-10-06"},"publish_date":"2015-10-06","publish_status":"0","recid":"58582","relation_version_is_last":true,"title":["標的アイソトープ治療　-最近の進歩と今後の展望-"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T22:14:26.415092+00:00"}